Three anti-coronavirus drugs prescribed in Japan, including molnupiravir, may be effective against the Omicron subvariant BA.5, according to a study published in the New England Journal of Medicine on July 21.
U.S. regulators authorize the emergency use of coronavirus vaccines developed by Pfizer Inc. and Moderna Inc. to include children as young as 6 months old.
A Japanese health ministry panel approves the use of an oral COVID-19 pill developed by Pfizer Inc., increasing the treatment options for people with mild symptoms.